Today, we welcomed Mamata Gokhale as our new Senior Vice President of Regulatory Affairs. An experienced leader in global regulatory strategy across all stages of clinical development, Dr. Gokhale will oversee regulatory engagement to support the advancement of our PROBODY® pipeline toward potential commercialization. Dr. Gokhale will be an incredible asset to our team as we work together to bring novel cancer therapies to patients in need. Read more: https://bit.ly/4diKHhX #BiotechLeaders #RegulatoryAffairs #LifeSciences #Oncology #CRC
CytomX Therapeutics
Biotechnology
South San Francisco, CA 12,669 followers
Transforming lives with safer, more effective therapies
About us
CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.
- Website
-
http://www.cytomx.com
External link for CytomX Therapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, CA
- Type
- Public Company
Locations
-
Primary
Get directions
151 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at CytomX Therapeutics
Updates
-
Today, we announced our Q1 2026 financial results, as well as key pipeline program updates for our first-in-class, EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC, and the CX-801 Phase 1 study in advanced melanoma. Learn more here: https://bit.ly/4uG8oXn We will also host a live conference call at 5 pm ET / 2 pm PT to discuss financial results alongside our pipeline updates. #BiotechEarnings #ColorectalCancer #CRC
-
-
On Thursday, May 7, we will host a conference call at 5 pm ET / 2 pm PT to report our Q1 2026 financial results. Participants may register for the conference call ahead of time using the link found in our latest release: http://bit.ly/428cmM5
-
-
We were honored to be named to the 2025 Bay Area Fast 500 list, and to see our name in lights on the Nasdaq tower last month. At CytomX, we are dedicated to treating cancer differently with safer and more effective therapies. #Nasdaq #Fast500 #Colorectalcancerawareness
-
-
Our team participated in #DressinBlueDay, a program started by the Colorectal Cancer Alliance, to raise awareness for colorectal cancer and honor all those whose lives have been impacted by this disease. At a time when colorectal cancer rates are rising, especially in individuals under the age of 50, it is vital to recognize the far-reaching impacts CRC has on patients, families, and caregivers. At CytomX, we are proud to be at the forefront of research and development that is revolutionizing the way we treat cancer. #DressinBlueDay #ColorectalCancerAwarenessMonth #EnoughCRC
-
-
We are proud to share positive Phase 1 expansion data for our first-in-class, EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC. The data shows consistent and durable responses with a manageable tolerability profile in heavily pretreated patients and reinforces the potential of Varseta-M to meaningfully improve the standard of care in late-line colorectal cancer. We look forward to continuing to advance Varseta-M towards late-phase development and presenting additional efficacy and safety data later this year. To learn more, read the full press release here: https://bit.ly/4s9EZUn #CRC #colorectalcancer #clinicaldata
-
Join us on Monday, March 16, for a presentation of our 2025 Q4 and full year financial results. Participants may join the live webcast at 8:00 am ET / 5:00 am PT. More details and link to register can be found in our press release: https://bit.ly/3Pgk5nS
-
-
Join our CEO and Chairman, Sean McCarthy, today 9:00 am PST for our company presentation at the 44th Annual J.P. Morgan Healthcare Conference. Listen to the live webcast or catch the replay here: https://bit.ly/49mNBPe
-
-
CytomX will be at the Piper Sandler 37th Annual Healthcare Conference today! Our CEO, Sean McCarthy, DPhil, is participating in a fireside chat at 1:00 pm ET. Join the live webcast or access the replay later from our website: https://lnkd.in/eZ86Q4P7
-
-
Our CEO, Sean McCarthy, DPhil, is participating in a fireside chat tomorrow, November 20, at the Jefferies London Healthcare Conference. Join the live webcast at 1:00 pm GMT / 8:00 am EST or access the replay from our website: https://lnkd.in/eZ86Q4P7
-